Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories AB (CHIX:RAYBs) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
RaySearch Laboratories AB Forward PE Ratio Related Terms
RaySearch Laboratories AB Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Forward PE Ratio Chart
RaySearch Laboratories AB Annual Data
Trend
2019-12
2020-12
2024-12
2025-12
Forward PE Ratio
33.33
31.65
23.38
24.09
RaySearch Laboratories AB Quarterly Data
2019-12
2020-03
2020-06
2020-09
2020-12
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
33.33
30.49
54.05
34.25
31.65
23.38
33.87
43.17
25.72
24.09
20.82
CHIX:RAYBS vs VEEV, BTSG, TEM: Forward PE Ratio Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Forward PE Ratio falls into.
RaySearch Laboratories AB Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
RaySearch Laboratories AB (CHIX:RAYBS) has a Forward PE Ratio of 26.64 as of Jul. 25, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RaySearch Laboratories AB and its competitors. According to the industry distribution chart, RaySearch Laboratories AB ranks #163 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 52.1%.
Is RaySearch Laboratories AB's Forward PE Ratio too high?
RaySearch Laboratories AB's current Forward PE Ratio is 26.64. The Healthcare Providers & Services industry median Forward PE Ratio is 18.32. RaySearch Laboratories AB's value of 26.64 is 45.4% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #163 out of 313 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #163 out of 313 companies for Forward PE Ratio. This places RaySearch Laboratories AB in the lower half of its industry. The industry median Forward PE Ratio is 18.32. RaySearch Laboratories AB's value of 26.64 is 45.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.32, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Forward PE Ratio of 26.64 is 45.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Forward PE Ratio is 26.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr266.48, compared to a current price of kr234.70 — trading 11.9% below its estimated fair value. The current Forward PE Ratio is 26.64 and 45.4% above the Healthcare Providers & Services industry median of 18.32. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Forward PE Ratio is 26.64 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be undervalued.
The current stock price of kr234.70 is trading 11.9% below its estimated GF Value™ of kr266.48.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for CHIX:RAYBS:
Forward PE Ratio: 26.64
GF Value™: kr266.48 vs. price of kr234.70 (11.9% below fair value)
Industry Position: 45.4% above the Healthcare Providers & Services median (#163 of 313)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
